What one share of Aclaris Therapeutics holds
We are a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. Our proprietary KINect drug discovery platform coupled with our integrated discovery approach to small and large molecules enables us to identify and advance product candidates designed to have superior target affinity, specificity and potency.
Aclaris Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.06 |
|---|---|
| Profit | −$0.59 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.48 |
| Cash and investments | $0.14 |
| Book value | $0.89 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | — | −$6.45 | — | — | — | −$8.47 |
| 2014 | — | −$6.15 | $0.24 | −$4.68 | — | −$7.60 |
| 2015 | — | −$3.79 | $0.08 | −$3.42 | — | — |
| 2016 | — | −$2.25 | $0.01 | −$1.63 | — | $6.50 |
| 2017 | $0.06 | −$2.44 | $0.04 | −$1.99 | — | $7.30 |
| 2018 | $0.19 | −$4.03 | $0.04 | −$3.10 | — | $5.22 |
| 2019 | $0.10 | −$3.90 | $0.04 | −$2.37 | — | $1.69 |
| 2020 | $0.15 | −$1.20 | $0.01 | −$0.92 | — | $0.83 |
| 2021 | $0.12 | −$1.60 | $0.01 | −$0.92 | — | $3.22 |
| 2022 | $0.46 | −$1.33 | $0.01 | −$1.05 | — | $2.96 |
| 2023 | $0.45 | −$1.27 | $0.02 | −$1.14 | — | $2.22 |
| 2024 | $0.24 | −$1.71 | $0.00 | −$0.26 | — | $1.44 |
| 2025 | $0.06 | −$0.53 | $0.00 | −$0.39 | — | $0.86 |
Common questions about Aclaris Therapeutics
How much does one share of Aclaris Therapeutics earn?
Over the last 12 months, Aclaris Therapeutics lost $0.59 for each share on $0.06 of sales.
Does Aclaris Therapeutics pay a dividend?
Aclaris Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Aclaris Therapeutics’s book value per share?
Aclaris Therapeutics’s book value is $0.89 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Aclaris Therapeutics have?
Each share of Aclaris Therapeutics has $0.14 of cash and investments, as of June 30, 2026.
What is Aclaris Therapeutics’s free cash flow per share?
−$0.48 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Aclaris Therapeutics bought back shares?
Aclaris Therapeutics’s share count rose about 11234% from 2013 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.